Mitochondrial damage is increasingly recognized as a key factor underlying neurodegenerative diseases including Alzheimer’s, Parkinson’s, and ALS. A new screening platform has identified a set of drug-like compounds that may protect them.
Mitochondrial damage is increasingly recognized as a key factor underlying neurodegenerative diseases including Alzheimer’s, Parkinson’s, and ALS. A new screening platform has identified a set of drug-like compounds that may protect them.